The War Over Cheaper Ozempic Won't End Well for Some Investors [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
Shares of Hims & Hers Health, the telehealth provider better known for its trendy commercials for erectile-dysfunction medications, are up more than 150% this year. The company said last month it would start offering compounded forms of the injections that use the same active ingredients as the popular drugs Ozempic and Wegovy. The stock soared before Hims & Hers sold even a single injection. Most Read from The Wall Street Journal Americans Chasing High Interest Rates Risk Falling Into a ‘Cash Trap' Volkswagen to Invest Up to $5 Billion Into EV Maker Rivian The Clock Is Ticking on Jane Fraser's Citigroup Turnaround New York Times to Move Podcasts Behind Paywall Forget Shale: Canada's Oil Sands Are Having Their Moment For now, given the Food and Drug Administration's rules allowing drugs to be compounded during shortages and the fact that most insurance policies don't cover obesity medications, Hims & Hers is filling an important void. But over the longer term, there ar
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- HIMS Stock Tumbles: Here's Why It's a Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Stock Drops 12.8% After Short Report [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health, Inc. (NYSE: HIMS) had its price target raised by analysts at Jefferies Financial Group Inc. from $14.00 to $23.00. They now have a "hold" rating on the stock.MarketBeat
- Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 5/6/24 - Beat
HIMS
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- HIMS's page on the SEC website